Iron-refractory iron deficiency anemia: New molecular mechanisms

Kidney International

Volumn 76, Issue 11, 2009, Pages 1137-1141

  Cui, Yujie ^a,b   Wu, Qingyu ^a,c   Zhou, Yiqing ^a  

^a SOOCHOW UNIVERSITY   (China)

^b TIANJIN MEDICAL UNIVERSITY   (China)

^c LERNER RESEARCH INSTITUTE   (United States)

Author keywords

End stage renal disease; EPO resistance; Hepcidin; Matriptase 2; TMPRSS6

Indexed keywords

BONE MORPHOGENETIC PROTEIN; FERROPORTIN; HEMOJUVELIN; HEPCIDIN; IRON; MATRIPTASE 2; RECOMBINANT ERYTHROPOIETIN; SERINE PROTEINASE; SMAD PROTEIN; UNCLASSIFIED DRUG;

GENE CONTROL; GENE EXPRESSION; GENE MUTATION; HOMEOSTASIS; HUMAN; IRON ABSORPTION; IRON BALANCE; IRON DEFICIENCY ANEMIA; IRON HOMEOSTASIS; IRON METABOLISM; KIDNEY FAILURE; MICROCYTIC ANEMIA; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; SHORT SURVEY; SIGNAL TRANSDUCTION;

EID: 72949105153     PISSN: 00852538     EISSN: 15231755     Source Type: Journal    
DOI: 10.1038/ki.2009.357     Document Type: Short Survey

References (49)

1. Elliott J, Mishler D, Agarwal R. Hyporesponsiveness to erythropoietin: causes and management. Adv Chronic Kidney Dis 2009; 16: 94-100.
2. Regidor DL, Kopple JD, Kovesdy CP et al. Associations between changes in hemoglobin and administered erythropoiesis-stimulating agent and survival in hemodialysis patients. J Am Soc Nephrol 2006; 17: 1181-1191.
3. Horl WH, Jacobs C, Macdougall IC et al. European best practice guidelines 14-16: inadequate response to epoetin. Nephrol Dial Transplant 2000; 15(Suppl 4): 43-50. (Pubitemid 30763265)
4. Eschbach JW, Cook JD, Scribner BH et al. Iron balance in hemodialysis patients. Ann Intern Med 1977; 87: 710-713.
5. NKF. NKF-K/DOQI Clinical Practice Guidelines for Anemia of Chronic Kidney Disease: update 2000. Am J Kidney Dis 2001; 37: S182-S238.
6. Drueke TB, Eckardt KU. Role of secondary hyperparathyroidism in erythropoietin resistance of chronic renal failure patients. Nephrol Dial Transplant 2002; 17(Suppl 5): 28-31.
7. Moe OW, Vazquez M, Kielar M. Iron metabolism in end stage renal failure: rationale for re-evaluation of parenteral iron therapy. Curr Opin Nephrol Hypertens 2003; 12: 145-151.
8. Stenvinkel P. Inflammation in end-stage renal disease: the hidden enemy. Nephrology (Carlton) 2006; 11: 36-41.
9. Besarab A, Amin N, Ahsan M et al. Optimization of epoetin therapy with intravenous iron therapy in hemodialysis patients. J Am Soc Nephrol 2000; 11: 530-538.
10. Thomas C, Thomas L. Anemia of chronic disease: pathophysiology and laboratory diagnosis. Lab Hematol 2005; 11: 14-23.
11. Andrews NC, Schmidt PJ. Iron homeostasis. Annu Rev Physiol 2007; 69: 69-85.
12. Knutson MD, Oukka M, Koss LM et al. Iron release from macrophages after erythrophagocytosis is up-regulated by ferroportin 1 overexpression and down-regulated by hepcidin. Proc Natl Acad Sci USA 2005; 102: 1324-1328.
13. Nemeth E, Ganz T. Regulation of iron metabolism by hepcidin. Annu Rev Nutr 2006; 26: 323-342.
14. Kulaksiz H, Theilig F, Bachmann S et al. The iron-regulatory peptide hormone hepcidin: expression and cellular localization in the mammalian kidney. J Endocrinol 2005; 184: 361-370.
15. Nicolas G, Bennoun M, Devaux I et al. Lack of hepcidin gene expression and severe tissue iron overload in upstream stimulatory factor 2 (USF2) knockout mice. Proc Natl Acad Sci USA 2001; 98: 8780-8785.
16. Nicolas G, Bennoun M, Porteu A et al. Severe iron deficiency anemia in transgenic mice expressing liver hepcidin. Proc Natl Acad Sci USA 2002; 99: 4596-4601.
17. Weinstein DA, Roy CN, Fleming MD et al. Inappropriate expression of hepcidin is associated with iron refractory anemia: implications for the anemia of chronic disease. Blood 2002; 100: 3776-3781.
18. Ashby DR, Gale DP, Busbridge M et al. Plasma hepcidin levels are elevated but responsive to erythropoietin therapy in renal disease. Kidney Int 2009; 75: 976-981.
19. Ganz T, Olbina G, Girelli D et al. Immunoassay for human serum hepcidin. Blood 2008; 112: 4292-4297.
20. Malyszko J, Mysliwiec M. Hepcidin in anemia and inflammation in chronic kidney disease. Kidney Blood Press Res 2007; 30: 15-30.
21. Tomosugi N, Kawabata H, Wakatabe R et al. Detection of serum hepcidin in renal failure and inflammation by using ProteinChip System. Blood 2006; 108: 1381-1387.
22. Peyssonnaux C, Zinkernagel AS, Datta V et al. TLR4-dependent hepcidin expression by myeloid cells in response to bacterial pathogens. Blood 2006; 107: 3727-3732.
23. Theurl I, Theurl M, Seifert M et al. Autocrine formation of hepcidin induces iron retention in human monocytes. Blood 2008; 111: 2392-2399.
24. Dallalio G, Law E, Means Jr RT. Hepcidin inhibits in vitro erythroid colony formation at reduced erythropoietin concentrations. Blood 2006; 107: 2702-2704.
25. Babitt JL, Huang FW, Wrighting DM et al. Bone morphogenetic protein signaling by hemojuvelin regulates hepcidin expression. Nat Genet 2006; 38: 531-539.
26. Truksa J, Peng H, Lee P et al. Bone morphogenetic proteins 2, 4, and 9 stimulate murine hepcidin 1 expression independently of Hfe, transferrin receptor 2 (Tfr2), and IL-6. Proc Natl Acad Sci USA 2006; 103: 10289-10293.
27. Wang RH, Li C, Xu X et al. A role of SMAD4 in iron metabolism through the positive regulation of hepcidin expression. Cell Metab 2005; 2: 399-409.
28. De Domenico I, Ward DM, Kaplan J. Hepcidin regulation: ironing out the details. J Clin Invest 2007; 117: 1755-1758.
29. Zhang AS, Enns CA. Iron homeostasis: recently identified proteins provide insight into novel control mechanisms. J Biol Chem 2009; 284: 711-715.
30. Lakhal S, Talbot NP, Crosby A et al. Regulation of growth differentiation factor 15 expression by intracellular iron. Blood 2009; 113: 1555-1563.
31. Weiss G, Goodnough LT. Anemia of chronic disease. N Engl J Med 2005; 352: 1011-1023.
32. Bologa RM, Levine DM, Parker TS et al. Interleukin-6 predicts hypoalbuminemia, hypocholesterolemia, and mortality in hemodialysis patients. Am J Kidney Dis 1998; 32: 107-114.
33. Laftah AH, Ramesh B, Simpson RJ et al. Effect of hepcidin on intestinal iron absorption in mice. Blood 2004; 103: 3940-3944.
34. Ludwiczek S, Aigner E, Theurl I et al. Cytokine-mediated regulation of iron transport in human monocytic cells. Blood 2003; 101: 4148-4154.
35. Theurl I, Aigner E, Theurl M et al. Regulation of iron homeostasis in anemia of chronic disease and iron deficiency anemia: diagnostic and therapeutic implications. Blood 2009; 113: 5277-5286.
36. Yang F, Liu XB, Quinones M et al. Regulation of reticuloendothelial iron transporter MTP1 (Slc11a3) by inflammation. J Biol Chem 2002; 277: 39786-39791.
37. Keithi-Reddy SR, Addabbo F, Patel TV et al. Association of anemia and erythropoiesis stimulating agents with inflammatory biomarkers in chronic kidney disease. Kidney Int 2008; 74: 782-790.
38. Ludwig H, Fritz E, Leitgeb C et al. Prediction of response to erythropoietin treatment in chronic anemia of cancer. Blood 1994; 84: 1056-1063.
39. Hooper JD, Campagnolo L, Goodarzi G et al. Mouse matriptase-2: identification, characterization and comparative mRNA expression analysis with mouse hepsin in adult and embryonic tissues. Biochem J 2003; 373: 689-702.
40. Du X, She E, Gelbart T et al. The serine protease TMPRSS6 is required to sense iron deficiency. Science 2008; 320: 1088-1092.
41. Folgueras AR, de Lara FM, Pendas AM et al. Membrane-bound serine protease matriptase-2 (Tmprss6) is an essential regulator of iron homeostasis. Blood 2008; 112: 2539-2545.
42. Finberg KE, Heeney MM, Campagna DR et al. Mutations in TMPRSS6 cause iron-refractory iron deficiency anemia (IRIDA). Nat Genet 2008; 40: 569-571.
43. Guillem F, Lawson S, Kannengiesser C et al. Two nonsense mutations in the TMPRSS6 gene in a patient with microcytic anemia and iron deficiency. Blood 2008; 112: 2089-2091.
44. Melis MA, Cau M, Congiu R et al. A mutation in the TMPRSS6 gene, encoding a transmembrane serine protease that suppresses hepcidin production, in familial iron deficiency anemia refractory to oral iron. Haematologica 2008; 93: 1473-1479.
45. Silvestri L, Guillem F, Pagani A et al. Molecular mechanisms of the defective hepcidin inhibition in TMPRSS6 mutations associated with iron-refractory iron deficiency anemia. Blood 2009; 8: 8.
46. Silvestri L, Pagani A, Nai A et al. The serine protease matriptase-2 (TMPRSS6) inhibits hepcidin activation by cleaving membrane hemojuvelin. Cell Metab 2008; 8: 502-511.
47. Dries DL, Victor RG, Rame JE et al. Corin gene minor allele defined by 2 missense mutations is common in blacks and associated with high blood pressure and hypertension. Circulation 2005; 112: 2403-2410.
48. Wang W, Liao X, Fukuda K et al. Corin variant associated with hypertension and cardiac hypertrophy exhibits impaired zymogen activation and natriuretic peptide processing activity. Circ Res 2008; 103: 502-508.
49. Wu Q, Xu-Cai YO, Chen S et al. Corin: new insights into the natriuretic peptide system. Kidney Int 2009; 75: 142-146.